Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
作者信息
Roozen Geert V T, Prins Margaretha L M, van Binnendijk Rob, den Hartog Gerco, Kuiper Vincent P, Prins Corine, Janse Jacqueline J, Kruithof Annelieke C, Feltkamp Mariet C W, Kuijer Marjan, Rosendaal Frits R, Roestenberg Meta, Visser Leo G, Roukens Anna H E
机构信息
Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
出版信息
Ann Intern Med. 2022 Dec;175(12):1771-1774. doi: 10.7326/M22-2089. Epub 2022 Oct 25.
Abstract
摘要
相似文献
1
Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
Ann Intern Med. 2022 Dec;175(12):1771-1774. doi: 10.7326/M22-2089. Epub 2022 Oct 25.
2
Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Vaccine. 2013 Aug 12;31(36):3688-94. doi: 10.1016/j.vaccine.2013.05.104. Epub 2013 Jun 13.
3
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
J Autoimmun. 2021 Dec;125:102744. doi: 10.1016/j.jaut.2021.102744. Epub 2021 Nov 10.
4
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1.
5
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
6
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.
7
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial.
Hum Vaccin. 2010 Apr;6(4):346-54. doi: 10.4161/hv.6.4.10961. Epub 2010 Apr 15.
8
Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2021 Feb 1;4(2):e2035693. doi: 10.1001/jamanetworkopen.2020.35693.
9
Approaches in broadening the neutralizing antibody response of the influenza vaccine.
Expert Rev Vaccines. 2021 Dec;20(12):1539-1547. doi: 10.1080/14760584.2021.1984887. Epub 2021 Oct 4.
10
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
Vaccine. 2022 Mar 15;40(12):1761-1767. doi: 10.1016/j.vaccine.2022.02.019. Epub 2022 Feb 21.
引用本文的文献
1
Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.
PLoS Negl Trop Dis. 2025 Jun 2;19(6):e0012956. doi: 10.1371/journal.pntd.0012956. eCollection 2025 Jun.
2
Tailoring mRNA lipid nanoparticles for antifungal vaccines.
PLoS Pathog. 2025 Apr 28;21(4):e1013091. doi: 10.1371/journal.ppat.1013091. eCollection 2025 Apr.
3
Advances in the development of microarray patches in biomedicine.
N Biotechnol. 2025 May 25;86:25-30. doi: 10.1016/j.nbt.2025.01.003. Epub 2025 Jan 14.
4
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents.
Immun Ageing. 2025 Jan 2;22(1):1. doi: 10.1186/s12979-024-00495-4.
5
Coagulation and inflammatory response after intramuscular or intradermal mRNA-1273 SARS-CoV-2 vaccine: secondary analysis of a randomized trial.
Res Pract Thromb Haemost. 2024 Apr 24;8(3):102419. doi: 10.1016/j.rpth.2024.102419. eCollection 2024 Mar.
6
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.
Mol Ther. 2024 May 1;32(5):1266-1283. doi: 10.1016/j.ymthe.2024.03.022. Epub 2024 Apr 2.
7
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial.
Vaccines (Basel). 2024 Jan 11;12(1):73. doi: 10.3390/vaccines12010073.
8
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial.
NPJ Vaccines. 2024 Jan 2;9(1):1. doi: 10.1038/s41541-023-00785-w.
9
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
J Infect Dis. 2023 Oct 3;228(7):868-877. doi: 10.1093/infdis/jiad133.
10
What has vaccination against COVID-19 in CKD patients taught us?
J Nephrol. 2023 Jun;36(5):1257-1266. doi: 10.1007/s40620-023-01640-w. Epub 2023 May 4.
Zotero 插件